Media Notification/Webcast Notification - Amgen and Abgenix to Conduct Conference Call and Webcast Regarding Panitumumab Pivotal
03 November 2005 - 2:00PM
PR Newswire (US)
THOUSAND OAKS, Calif. and FREMONT, Calif., Nov. 3
/PRNewswire-FirstCall/ -- -Amgen (NASDAQ:AMGN) and Abgenix, Inc.
(NASDAQ:ABGX) will host a joint conference call on November 3 at
8:00 a.m. Pacific Time to discuss the top-line results of a
recently completed pivotal study of panitumumab. A separate press
release announcing these results is being issued this morning. Live
audio of the conference call will be simultaneously broadcast over
the Internet and will be available to members of the news media,
investors and the general public. To participate in the conference
call, please dial 877-817-2450 or 706-634-7548 fifteen minutes
before start time. The pass code for the live call is 2201994. A
telephonic replay of the call will be available by dialing
800-642-1687 or 706-645-9291. The replay participant code is
2201994. The webcast of the conference can be found on Amgen's Web
site, http://www.amgen.com/, under Investors, and on Abgenix's Web
site, http://www.abgenix.com/. The webcast will be archived and
available for replay at least 72 hours after the event. About Amgen
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of
the first companies to realize the new science's promise by
bringing safe and effective medicines from lab, to manufacturing
plant, to patient. Amgen therapeutics have changed the practice of
medicine, helping millions of people around the world in the fight
against cancer, kidney disease, rheumatoid arthritis, and other
serious illnesses. With a broad and deep pipeline of potential new
medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our
pioneering science and our vital medicines, visit
http://www.amgen.com/. About Abgenix Abgenix is a biopharmaceutical
company focused on the discovery, development and manufacturing of
fully human therapeutic antibodies. The company's antibody
development platform includes a leading technology and
state-of-the-art manufacturing capabilities that enable the rapid
generation, selection and production of high affinity, fully human
antibody product candidates to a variety of disease targets.
Abgenix leverages its leadership position in human antibody
technology to build a diversified product portfolio through its own
development efforts and the establishment of collaborations with
multiple pharmaceutical and biotechnology companies. For more
information on Abgenix, visit the company's website at
http://www.abgenix.com/. DATASOURCE: Abgenix, Inc. CONTACT: media,
Trish Hawkins, +1-805-447-4587, or investors, Arvind Sood,
+1-805-447-1060, both of Amgen; or Greg Mann of Abgenix,
+1-510-284-6566 Web site: http://www.amgen.com/ Web site:
http://www.abgenix.com/
Copyright
Abgenix (NASDAQ:ABGX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Abgenix (NASDAQ:ABGX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Abgenix (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere Abgenix (MM) News-Artikel